KEEP UP WITH WHAT’S HAPPENING

BLOG

13
Feb 2019

Q. Isn’t there a risk that this will accelerate the adoption of drugs that aren’t ready and aren’t safe yet?

By boadmin11

This isn’t a trade-off between speed and safety. This is about getting medicines designed specifically for patients who express biological characteristics (biomarkers) that increase the odds that a treatment will actually work for them. FDA is streamlining approvals for these treatments and personalized medicine can arguably have better safety and efficacy profiles than one-size fits all medicine of today.

STAY IN TOUCH

Sign up for email updates and news from SequenceMe.
Something went wrong. Please check your entries and try again.

Recent Posts

Latest Tweets